Related Experiment Video

Updated: May 1, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Elena Verzoni1, Paolo Grassi1, Isabella Testa1

  • 1Department of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Pharmacogenomics and Personalized Medicine
|April 10, 2014
PubMed

Insights

Axitinib, a vascular endothelial growth factor receptor inhibitor, demonstrated superior progression-free survival compared to sorafenib in metastatic renal cell carcinoma patients. This targeted therapy offers an effective treatment option with a favorable safety profile.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Antiangiogenesis therapies have advanced significantly, with new agents approved for metastatic renal cell carcinoma (mRCC).
  • Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors are key in managing mRCC.
  • Axitinib represents a third-generation VEGFR inhibitor with promising therapeutic potential.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, and clinical efficacy of axitinib in renal cell carcinoma (RCC) treatment.
  • To evaluate axitinib's role in managing metastatic renal cell carcinoma.
  • To discuss the safety and quality of life aspects associated with axitinib therapy.

Main Methods:

  • Review of existing literature on axitinib's pharmacology and pharmacokinetics.
  • Analysis of data from a Phase III clinical trial comparing axitinib to sorafenib in previously treated mRCC patients.
  • Assessment of safety profiles and quality of life metrics.

Main Results:

  • Axitinib demonstrated longer progression-free survival compared to sorafenib in patients with metastatic renal cell carcinoma.
  • The drug exhibited an acceptable safety profile and contributed to a good quality of life for patients.
  • Pharmacokinetic properties of axitinib suggest selective therapeutic effects and enhanced safety.

Conclusions:

  • Axitinib is an effective treatment option for previously treated metastatic renal cell carcinoma patients, offering improved progression-free survival.
  • Its favorable safety and quality of life profile make it a valuable therapeutic choice.
  • Further clinical trials are warranted to explore axitinib's efficacy in the adjuvant and neoadjuvant settings.
Keywords:
angiogenesisaxitinibrenal cell carcinomavascular endothelial growth factor receptor

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K